Polycystic ovary syndrome: Pathophysiology, molecular aspects and clinical implications

Panminerva Medica

Volumn 50, Issue 4, 2008, Pages 267-278

  Nardo, L G ^a   Patchava, S ^a   Laing, I ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Hyperandrogenism; Hyperinsulinism; Insulin resistance; Neuroendocrine systems, physiology; Polycystic ovary syndrome, diagnosis; Polycystic ovary syndrome, physiopatology

Indexed keywords

ANDROGEN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR;

ADRENAL GLAND; DIABETES MELLITUS; FEMALE; HUMAN; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; OVARY; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; SECRETION;

ADRENAL GLANDS; ANDROGENS; ANTI-MULLERIAN HORMONE; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; LUTEINIZING HORMONE; OVARY; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 59549087402     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:671-3.
2. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome: a hypothesis. J Endocrinol 2002;174:1-5.
3. The ESHRE/ASRM-Sponsored Rotterdam Consensus Meeting. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7.
4. Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF, Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res 1998;53:217-6.
5. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c 17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-23.
6. De Vane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975;121:496-500.
7. Lobo RA, Kletzky OA, Campeau JD, di Zerega GS. Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome. Fertil Steril 1983;39:674-8.
8. Mavroudis K, Evans A, Mamtora H, Anderson DC, Robertson WR. Bioactive LH in women with polycystic ovaries and the effect of gonadotrophin suppression. Clin Endocrinol (Oxf) 1988;29:633-41.
9. Olukoga AO, Mitchell R, Walton L, Robertson WR, Laing I. Differences in serum luteinizing hormone measurements by immunoradiometric assay induced by kinetic manipulation of assay conditions are dependent on the endocrine milieu of serum. Ann Clin Biochem 1996;33:107-11.
10. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976;57:1320-9.
11. Tapanainen JS, Koivunen R, Fauser BC, Taylor AE, Clayton RN, Rajkowa M, et al. A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J Clin Endocrinol Metab 1999;84:1711-5.
12. Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001;86:1318-23.
13. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728-31.
14. Pagán YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab 2006;91:1309-16.
15. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-52.
16. Ropelato MG, Garcia-Rudaz MC, Castro-Femandez C, Ulloa-Aguirre A, Escobar ME, Barontini M, et al. A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome. J Clin Endocrinol Metab 1999;84:4629-36.
17. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
18. Rosner W. An extraordinarily inaccurate assay for free testosterone is still with us. J Clin Endocrinol Metab 2001;86:2903.
19. Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:265-93.
20. Middle JG. Dehydroepiandrostenedione sulphate interferes in many direct immunoassays for testosterone. Ann Clin Biochem 2007;44:173-7.
21. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003;49:1381-95.
22. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest 2005;28:28-31.
23. Anderson DC, Hopper BR, Lasley BL, Yen SS. A simple method for the assay of eight steroids in small volumes of plasma. Steroids 1976;28:179-96.
24. Thienpont LM, Van Uytfanghe K, Blincko S, Ramsay CS, Xie H, Doss RC, et al. State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography-tandem mass spectrometry. Clin Chem 2008;54:1290-7.
25. Cawood ML, Field HP, Ford CG, Gillingwater S, Kicman A, Cowan D, et al. Testosterone measurement by isotope-dilution liquid chromatography- tandem mass spectrometry: validation of a method for routine clinical practice. Chem 2005;51:1472-9.
26. Gallagher LM, Owen LJ, Keevil BG. Simultaneous determination of androstenedione and testosterone in human serum by liquid chromatography-tandem mass spectrometry. Ann Clin Biochem 2007;44:48-56.
27. Randall VA, Thornton MJ, Hamada K, Redfern CP, Nutbrown M, Ebling FJ, et al. Androgens and the hair follicle. Cultured human dermal papilla cells as a model system. Ann N Y Acad Sci 1991;642:355-75.
28. Hodgins MB, Choudhry R, Parker G, Oliver RF, Jahoda CA, Withers AP, et al. Androgen receptors in dermal papilla cells of scalp hair follicles in male pattern baldness. Ann NY Acad Sci 1991;642:448-51.
29. Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992;133:467-75.
30. Rosenfield RL, Barnes RB, Cara JF, Lucky AW. Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril 1990;53:785-91.
31. Hillier SG, Tetsuka M, Fraser HM. Location and developmental regulation of androgen receptor in primate ovary. Hum Reprod 1997;12:107-11.
32. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci USA 1990;87:3640-4.
33. Andersson S, Berman DM, Jenkins EP, Russell DW. Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature 1991;354:159-61.
34. Hamada K, Thornton MJ, Laing I, Messenger AG, Randall VA. The metabolism of testosterone by dermal papilla cells cultured from human pubic and axillary hair follicles concurs with hair growth in 5 alpha-reductase deficiency. J Invest Dermatol 1996;106:1017-22.
35. Hoffman R, Happle R. Current understanding of androgenetic alopecia; part 1, etiopathogenesis. Eur J Dermatol 2000;10:319-27.
36. Thornton MJ, Laing I, Hamada K, Messenger AG, Randall VA. Differences in testosterone metabolism by beard and scalp hair follicle dermal papilla cells. Clin Endocrinol (Oxf) 1993;39:633-9.
37. Itami S, Inui S. Role of androgen in mesenchymal epithelial interactions in human hair follicle. J Investig Dermatol Symp Proc 2005;10:209-11.
38. SkaΠba P, Dabkowska-Huc A, Kazimierczak W, Samojedny A, Samojedny MP, CheΠmicki Z. Content of 5-alpha-reductase (type 1 and type 2) mRNA in dermal papillae from the lower abdominal region in women with hirsutism. Clin Exp Dermatol 2006;31:564-70.
39. Falsetti L, GamberaA, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999;141:361-7.
40. Petrone A, Civitillo RM, Galante L, Giannotti F, D'Antò V, Rippa G, et al. Usefulness of a 12-month treatment with finasteride in idiophathic and polycystic ovary syndrome-associated hirsutism.Clin Exp Obstet Gynecol 1999;26:213-6.
41. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5 alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab 2006;91:4085-91.
42. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:113-8.
43. Hoffmann R, Rot A, Niiyama S, Billich A. Steroid sulfatase in the human hair follicle concentrates in the dermal papilla. J Invest Dermatol 2001;117:1342-8.
44. Chin D, Shackleton C, Prasad VK, Kohn B, David R, Imperato-McGinley J, et al. Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome. J Pediatr Endocrinol Metab 2000;13:253-8.
45. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab 2003;88:5907-13.
46. Miles RA, Cassidenti DL, Carmina E, Gentzschein E, Stanczyk FZ, Lobo RA. Cutaneous application of an androstenedione gel as an in vivo test of 5 alpha-reductase activity in women. Fertil Steril 1992;58:708-12.
47. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2760-6.
48. Sawaya ME, Price VH. Different levels of 5 alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;109:296-300.
49. Thornton MJ. The biological actions of estrogens on skin. Exp Dermatol 2002;11:487-502.
50. Thornton MJ, Nelson LD, Taylor AH, Birch MP, Laing I, Messenger AG. The modulation of aromatase and estrogen receptor alpha in cultured human dermal papilla cells by dexamethasone: a novel mechanism for selective action of estrogen via estrogen receptor beta? J Invest Dermatol 2006;126:2010-8.
51. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM. Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. MoI Endocrinol 1997;11:1971-84.
52. Randall VA, Thornton MJ, Hamada K, Messenger AG. Mechanism of androgen action in cultured dermal papilla cells derived from human hair follicles with varying responses to androgens in vivo. J Invest Dermatol 1992;98:86S-91S.
53. Bergh C, Olsson JH, Selleskog U, Hillensjö T. Steroid production in cultured thecal cells obtained from human ovarian follicles. Hum Reprod 1993;8:519-24.
54. Nestler JE, Jacubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001-5.
55. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:1158-65.
56. Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1997;47:93-9.
57. Nelson VL, Legro RS, Strauss JF 3rd, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946-57.
58. Nelson VL, Qin KN, Rosenfield RL, Wood JR, Penning TM, Legro RS, et al. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. Clin Endocrinol Metab 2001;86:5925-33.
59. Wachs DS, Coffler MS, Malcom PJ, Shimasaki S, Chang RJ. Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:1827-33.
60. Glister C, Richards SL, Knight PG. Bone morphogenetic proteins (BMP) -4, -6, and -7 potently suppress basal and luteinizing hormone-induced androgen production by bovine theca internal cells in primary culture: could ovarian hyperandrogenic dysfunction be caused by a defect in thecal BMP signaling? Endocrinology 2005;146:1883-92.
61. Rice S, Kamal O, Whitehead S, Mason H. Stage specific expression of androgen receptor, follicle stimulating hormone receptor and anti-Mullerian hormone receptor type II in single isolated human preantral follicles: relevance to polycystic ovaries. J Clin Endocr Metab 2007;92:1034-40.
62. Tetsuka M, Whitelaw PF, Bremner WJ, Millar MR, Smyth CD, Hillier SG. Developmental regulation of androgen receptor in rat ovary. J Endocrinol 1995;145:535-43.
63. Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kemnitz JW. Insights into PCOS from studies in pre-androgenised female rhesus monkeys. Trends Endocrinol Metab 1999;9:62-7.
64. West C, Foster DL, Evans NP, Padmanbhan V. Intra follicular activin availability is altered in pre-natally androgrenised lambs. Mol Cell Endocrinol 2001;185:51-9.
65. Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle stimulating hormone interactions in primate ovarian follicle development. J Clin Endocr Metab 1999;84:2951-6.
66. McNatty KP, Makris A, Reinhold VN, De Grazia C, Osathanondh R, Ryan KJ. Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity. Steroids 1979;34:429-43.
67. Jakimiuk AJ, Weitsman SR, Magoffin DA. 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:2414-8.
68. Azziz R, Black V, Hines GA, Fox LM, Boots LR. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 1998;83:2317-23.
69. Moran C, Reyna R, Boots LS, Azziz R. Adrenocortical hyper-responsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess. Fertil Steril 2004;81:126-31.
70. Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med 1994;330:460-5.
71. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, et al. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 2003;34:434-9.
72. Zhou R, Bird IM, Dumesic DA, Abbott DH. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:6630-7.
73. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002;143:1076-84.
74. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic recruitment. Mol Hum Reprod 2004;10:77-83.
75. Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-mullerian hormone inhibits initiation of growth of human primordial follicles in vitro. Hum Reprod 2006;21:2223-7.
76. Cook C, Siow Y, Brenner A, Fallal M. Relationship between serum Mullerian inhibiting cubstance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002;77:141-6.
77. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, et al. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92:240-5.
78. Fanchin R, Schonauer L, Righini C, Guibourdenche J, Frydman R, Taeib J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-7.
79. Nardo LG, Christodoulou D, Gould D, Roberts S, Fitzgerald CT, Laing I. Anti-Mullerian hormone levels and antral follicle count in women enrolled in IVF cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol 2007, July 24, [Epub ahead of print].
80. Stubbs SA, Hardy K, Da Silva-Buttkuss P, Stark J, Webber JL, Flanagan AM, et al. Anti-Mullerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J Clin Endocr Metab 2005;90:5536-43.
81. Das M, Gillott DJ, Saridogan E, Djahanbakhch O. Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 2008;23:2122-6.
82. Catteau-Jonard S, Jamin SP, Leclerc A, Gonzales J, Dewailly D, di Clemente N. Anti-Mullerian hormone, its receptor, FSH receptor and androgen receptor genes are overexpressed by granulose cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008, Aug 12, [Epub ahead of print].
83. Recabarren SE, Sir-Petermann T, Rios R, Maliqueo M, Echiburu B, Smith R, et al. Pituitary and testicular function in sons of women with polycystic ovary syndrome from infancy to adulthood. J Clin Endocrinol Metab 2008;93:3318-24.
84. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of Anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocr Metab 2003;88:5957-62.
85. La Marca A, Orvieto R, Giulini S, Jasonni V, Volpe A, De Leo V. Mullerian-inhibiting substance in women with polycystic ovary syndrome: a relationship with hormonal and metabolic characteristics. Fertil Steril 2003;82:970-2.
86. Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with the polycystic ovary syndrome. Hum Reprod 2008;23:952-7.
87. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005;20:1820-6.
88. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-6.
89. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in non obese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983;57:356-9.
90. Dunaif A, Segal KR, Futterweit W, Dobransky A. Profound insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
91. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
92. Yates AP, Laing I. Age-related increase in haemoglobin A1c and fasting plasma glucose is accompanied by a decrease in Beta cell function without change in insulin sensitivity: evidence from a cross -sectional study of hospital personnel. Diabet Med 2002;19:254-8.
93. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003;88:1528-33.
94. Heald A, Whitehead S, Anderson S, Cruickshank K, Riste L, Laing I, et al. Screening for insulin resistance in women with polycystic ovarian syndrome. Gynecol Endocrinol 2005;20:84-91.
95. Taylor AE. Insulin-lowering medications in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2000;27:583-95.
96. Nestler JE. Sex-hormone binding globulin: a marker for hyperinsulinaemia and/or insulin resistance. J Clin Endocrinol Metab 1993;76:273-4.
97. Laing I, Olukoga AO, Gordon C, Boulton AJ. Serum sex-hormone-binding globulin is related to hepatic and peripheral insulin sensitivity but not to beta-cell function in men and women with type 2 diabetes mellitus. Diabet Med 1998;15:473-9.
98. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-10.
99. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:3110-6.
100. Wu XK, Zhou SY, Liu JX, Pöllänen P, Sallinen K, Mäkinen M, et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril 2003;80:954-65.
101. Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A. Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 2006;55:751-9.
102. Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocr Metab 2006;91:22-4.
103. Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13:251-7.
104. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovarian syndrome and their first degree relatives. J Clin Endocrinol Metab 2001;86:2027-31.
105. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of noninsulin-dependent diabetes mellitus. J Clin Invest 1995;96:520-7.
106. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
107. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90:3236-42.
108. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-51.
109. Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril 1999;72:990-5.
110. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
111. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993;42:945-9.
112. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998;69:236-41.
113. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Løvik A, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;44:611-6.
114. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-16.
115. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
116. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013-7.
117. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2.
118. Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 2005;20:200-8.
119. Balen AH, Tan SL, MacDougall J, Jacobs HS. Miscarriage rates following in vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993;8:959-64.
120. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524-9.
121. Homburg R, Levy T, Berkovitz D, Farchi J, Feldberg D, Ashkenazi J, et al. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome Fertil Steril 1993;59:527-31.
122. Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006;55:345-52.
123. Bayraktar F, Dereli D, Ozgen AG, Yilmaz C. Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr J 2004;51:601-8.
124. Ciampelli M, Lanzone A, Caruso A. Insulin in obstetrics: a main parameter in the management of pregnancy. Hum Reprod Update 1998;4:904-14.
125. Thatcher SS, Jackson EM. Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. Fertil Steril 2006;85:1002-9.
126. Fowler DJ, Nicolaides KH, Miell JP. Insulin-like growth factor binding protein-1 (IGFBP-1): a multifunctional role in the human female reproductive tract. Hum Reprod Update 2000;6:495-504.
127. Cresswell JL, Barker DJ, Osmond C, Egger P, Phillips DI, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997;350:1131-5.
128. Jensen RB, Chellakooty M, Vielwerth S, Vaag A, Larsen T, Greisen G, et al. Intrauterine growth retardation and consequences for endocrine and cardiovascular diseases in adult life: does insulin-like growth factor-I play a role? Horm Res 2003;60 (Suppl 3):136-48.
129. Glueck CJ, Bornovali S, Pranikoff J, Goldenberg N, Dharashivkar S, Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 2004;21:829-36.